05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
While this week’s Update does not include stories about Coronavirus and its potentially disastrous ...
Read More >
On January 10, 2020, the Department of Justice’s Antitrust Division (“DOJ”) and the Federal Trade...
Read More >
This past February we reported that the Supreme Court agreed to review the Fifth Circuit’s ruling i...
Read More >
On June 19th, the New York State Senate and Assembly voted to pass omnibus legislation greatly stren...
Read More >
Adjustments to the reporting thresholds under the Hart-Scott-Rodino Antitrust Improvements Act of 19...
Read More >
As we previously reported, effective October 30, 2019, Westchester County, NY employers are required...
Read More >